Liza Laws, Author at Labiotech.eu

News and Trends 23 Jun 2022

Osivax gets €10M influenza vaccine grant

A grant of €10 million ($10.5 million) has been secured by pharmaceutical company Osivax to support a vaccine against influenza. The biopharma company develops vaccines to provide broad-spectrum protection against highly mutating infectious viruses and diseases. It announced today (June 23) that it has secured the funds from Bpifrance to support the further clinical development […]

June 23, 2022 - 2 minutesmins - By Liza Laws

News and Trends 23 Jun 2022

Shanghai biotech secures $80 million to advance products

A bio-manufacturing company based in Shanghai has bagged $80 million in funding to advance its bio-based supplies. Mojia Biotech said it would use the funds to commercialize its Viridimin brand of animal-feed additives, scale up manufacturing capacity for Aliphane series of bio-based materials, advance its product pipeline and expand its global research and development capabilities. […]

June 23, 2022 - 2 minutesmins - By Liza Laws

News and Trends 22 Jun 2022

Roquefort Therapeutics buys UK biotech in return for shares

Medical biotechnology company, Roquefort Therapeutics, has conditionally agreed to buy UK biotech Oncogeni Ltd in return for shares. Oncogeni develops novel patented cancer medicines, and will receive 50 million shares, worth just under £4 million ($4.9 million). Acquisition In light of the acquisition, Oncogeni co-founder Ajan Reginald will become chief executive of the group, and […]

June 22, 2022 - 2 minutesmins - By Liza Laws

News and Trends 22 Jun 2022

Millions invested for progression of Lyme disease vaccine

Pfizer has agreed to invest €90.5 million ($95 million) towards a vaccination for Lyme disease. A deal has been struck with Valneva SE that will see the start of the phase 3 study of the disease’s vaccine candidate, VLA15. This is scheduled for the third quarter of this year. The investment will represent 8.1% of […]

June 22, 2022 - 2 minutesmins - By Liza Laws

News and Trends 22 Jun 2022

US Toddlers and children to receive Covid-19 vaccine after emergency approval granted

Emergency authorization was granted for the use of the Pfizer-BioNTech Covid-19 vaccines on children from six months old to under five years of age. The US Food and Drug Administration made the authorization on Friday (June 17). All children ages 6 months and up are now eligible to receive the COVID-19 vaccine, following the US […]

June 22, 2022 - 3 minutesmins - By Liza Laws

News and Trends 21 Jun 2022

Drug to treat esophageal cancer approved in China

A new drug application for first-line treatment of unresectable, locally advanced, recurrent or metastatic esophageal squamous cell carcinoma (ESCC) has been approved in China. Biopharmaceutical company Innovent Biologics Inc together with Eli Lilly and Company were jointly granted the approval for the supplemental new drug application for TYVYT, a sintilimab injection, combined with cisplatin plus […]

June 21, 2022 - 2 minutesmins - By Liza Laws

News and Trends 21 Jun 2022

New data demonstrates clinical potential of Inivata’s RaDaR technology for breast cancer

Data supporting the detection of minimal residual disease (MRD) has highlighted potential to provide an early predictor of tumor recurrence in patients who have had breast cancer. Liquid biopsy company Inivata announced the new data in support of its new RaDaR assay for the detection of MRD in those with high-risk hormone receptor-positive (HR+), human […]

June 21, 2022 - 3 minutesmins - By Liza Laws

News and Trends 21 Jun 2022

Treatment for highly-sensitized kidney transplant patients approved and recommended

Treatment offered by Hansa Biopharma for the densensitization of highly sensitized adults prior to kidney transplants from deceased donors has been recommended by the UK’s National Institute for Health and Care Excellence (NICE). NICE considers Idefirix (imlifidase), made by Hansa, a Swedish company that specializes in enzyme technology for rare immunological conditions, to be a […]

June 21, 2022 - 3 minutesmins - By Liza Laws

News and Trends 17 Jun 2022

ImCheck raises €96M in funding round

French biotech company ImCheck has announced funding of €96 million ($101.5 million) to investigate antibody drugs with the ability to activate the powerful immune cells called gamma delta T (gdT). The Marseille-based company hopes it will reach a wider range of cancer immunotherapy with the antibody drugs that include a lead candidate in the development […]

June 17, 2022 - 3 minutesmins - By Liza Laws

News and Trends 16 Jun 2022

Taiwanese company sells knee pain drug for $30 million

A clinical stage pharma company specializing in developing nanomedicines will receive $30 million in exchange for rights to an injectable treatment for osteoarthritis (OA). In one of the largest deals in Taiwan’s biotech sector, TLC Biosciences will receive the upfront payment with potential to earn a further $110m if the treatment targeting knee pain is […]

June 16, 2022 - 3 minutesmins - By Liza Laws

News and Trends 16 Jun 2022

Spirea raises £2.4M to develop antibody drug conjugates in cancer

Funding of £2.4 million ($2.9 million) has been secured by UK-based company, Spirea Limited, to advance a new generation of antibody drug conjugate (ADC) therapeutics. The company will use the funds to initiate its pipeline of ADCs in the treatment of solid tumors where they say there is a high unmet need. Targeted therapies, especially […]

June 16, 2022 - 3 minutesmins - By Liza Laws

Resources

Categories

The twelve hottest biotech companies in the Boston area

Biotech bankruptcies: what to expect in 2024 following a record year?

Approaches

Therapeutic areas

RNA editing set to take off: could it outperform gene editing?

Future of cancer treatment: what will therapy look like in 2034?

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

The twelve hottest biotech companies in the Boston area

Biotech bankruptcies: what to expect in 2024 following a record year?

RNA editing set to take off: could it outperform gene editing?

Future of cancer treatment: what will therapy look like in 2034?

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Liza Laws

Articles by Liza Laws

Osivax gets €10M influenza vaccine grant

Shanghai biotech secures $80 million to advance products

Roquefort Therapeutics buys UK biotech in return for shares

Millions invested for progression of Lyme disease vaccine

US Toddlers and children to receive Covid-19 vaccine after emergency approval granted

Drug to treat esophageal cancer approved in China

New data demonstrates clinical potential of Inivata’s RaDaR technology for breast cancer

Treatment for highly-sensitized kidney transplant patients approved and recommended

ImCheck raises €96M in funding round

Taiwanese company sells knee pain drug for $30 million

Spirea raises £2.4M to develop antibody drug conjugates in cancer

Subscribe to our newsletter to get the latest biotech news!